Creme RIFM™

Creme RIFM Model and Software Service

Creme RIFM Model Benefits

The Creme RIFM model provides a detailed aggregate systemic and dermal exposure assessment system for fragrance compounds. The model has data to assess exposure for consumers across Europe and the USA. The benefits to RIFM members of using this new model include:

Avoiding over-estimation of exposure

The model will replace the previous overly conservative and unrealistic methods for estimating aggregate exposure

More accurate and realistic evaluation of fragrance ingredient exposure

No longer a need to assume that a fragrance ingredient is used in every consumer product at the maximum concentration level

No longer a need to assume that every consumer uses every single product type every day.

Product usage data now based on real habits and practice information

Reduction in the need for clinical toxicity testing and studies

Delivers significant resource and budget savings as these tests are time consuming and expensive

Satisfying the European Commission’s request for information on aggregate exposure when assessing dermal sensitization

Satisfying the USA Toxic Substances Control Act (TSCA) Reform legislation that specifically asks for aggregate exposure of a chemical ingredient

Providing a unified approach to Chemical Safety Assessments under REACH

Creme RIFM Model Details

The Creme RIFM model includes detailed usage data for over 36,000 consumers representing the European and US populations. This robust population sample allows generation of accurate and realistic exposure results. The database contains detailed usage information on the following products: